Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

The IL-1R pathway is a potential target in primary cutaneous anaplastic large cell lymphomas. CD30/TNFRSF8 is a consistent biomarker for classical Hodgkin's and anaplastic large cell lymphoma and is a ...

The primary driver of this market expansion is the shift ... of 4.65% during 2024-2034. Cutaneous T-Cell Lymphoma Market: The 7 major Cutaneous T-cell-lymphoma market reached a value of US$ 428.2 ...

According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 72 ... lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), systemic sclerosis (scleroderma), polymyositis, ...

PF-08046045 is under clinical development by Pfizer and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase I drugs for Cutaneous T-Cell Lymphoma have an 84% phase ...

Hodgkin lymphoma (formerly known as Hodgkin disease), which involves an abnormal type of lymphocyte called Reed-Sternberg cells Non-Hodgkin lymphoma, which does not contain Reed-Sternberg cells ...

American Cancer Society. Key statistics for lymphoma of the skin. Lima M. Cutaneous primary B-cell lymphomas: From diagnosis to treatment. An Bras Dermatol. 2015;90(5):687-706. American Cancer Society ...

Mucosa-associated lymphoid tissue (MALT) lymphoma is rarely observed in the gallbladder, and its diagnosis before surgery is difficult. This report describes a case of primary MALT lymphoma of the ...

Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. The American Cancer Society’s estimates for non-Hodgkin lymphoma in 2025 are: ...